Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review

References

• Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527–1538.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D34–D41.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents, American Heart Association, American College of Chest Physicians, American Thoracic Society, Inc., Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–1619.
   Google Scholar
• Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449–475.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Gomez-Sanchez MA. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(Suppl 1):S55–S66.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537.
   PubMed Web of Science ®Google Scholar
• Howard LS, Ferrari P, Mehta S. Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Eur Respir Rev. 2014;23(134):458–468.
   PubMedGoogle Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(Suppl D):D60–D72.
   PubMedGoogle Scholar
• Lexicomp Online® [database on the Internet]. Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; April 1, 2015. Available from: http://online.lexi.com/crlsql/servlet/crlonline. Accessed October 9, 2015.
   Google Scholar
• Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159–165.
   PubMed Web of Science ®Google Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665.
   PubMed Web of Science ®Google Scholar
• Hemnes AR. Pulmonary arterial hypertension treatment guidelines: new answers and even more questions. Chest. 2014;146(2):239–241.
   PubMed Web of Science ®Google Scholar
• Tonelli AR, Zein J, Ioannidis JP. Geometry of the randomized evidence for treatments of pulmonary hypertension. Cardiovasc Ther. 2013; 31(6):e138–e146.
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214–221.
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012.
   PubMed Web of Science ®Google Scholar
• Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;91:7583–7587.
   PubMed Web of Science ®Google Scholar
• Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725–748.
   PubMed Web of Science ®Google Scholar
• Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930–938.
   PubMed Web of Science ®Google Scholar
• Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep. 2003;4:457–465.
   PubMedGoogle Scholar
• Adcirca® (tadalafil) tablets for oral administration [package insert]. Indianapolis, IN: Eli Lily and Company; 2014.
   Google Scholar
• Revatio® (sildenafil) tablets, for oral use [package insert]. New York, NY: Pfizer Labs; 2012.
   Google Scholar
• Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280–288.
   PubMed Web of Science ®Google Scholar
• Frantz RP, Durst L, Burger CD, et al. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. J Cardiovasc Pharmacol Ther. 2014; 19(6):550–557.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48(5):610–618.
   PubMed Web of Science ®Google Scholar
• Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11–S14.
   PubMed Web of Science ®Google Scholar
• Adempas® (riociguat) tablets, for oral use [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2014.
   Google Scholar
• Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension: Markov state-transition decision analysis model. Clin Drug Investig. 2009;29(10):635–646.
   PubMed Web of Science ®Google Scholar
• Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13(49):1–320.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2004;44(7):1488–1496.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: a prospective study. Indian Heart J. 2007; 59(4):329–335.
   PubMedGoogle Scholar
• Bharani A, Patel A, Saraf J, Jain A, Mehrotra S, Lunia B. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59(4):323–328.
   PubMedGoogle Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903.
   PubMed Web of Science ®Google Scholar
• Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012;33(5):683–688.
   PubMed Web of Science ®Google Scholar
• Shlobin OA, Brown AW, Weir N, Ahmad S, Lemma M, Nathan SD. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. Lung. 2012;190(5):573–578.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Brundage BH, Galiè N, et al; PHIRST Study Group. Tadalafil for the treatment of pulmonary arterial hypertension a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768–774.
   PubMed Web of Science ®Google Scholar
• Sabri MR, Beheshitan E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol. 2014;35(4):699–704.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Traiger G, Hill W, Zhang L, Doran AK. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013;31(5):274–279.
   PubMed Web of Science ®Google Scholar
• Lichtblau M, Harzheim D, Ehlken N, et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung. 2015;195(1):105–112.
   Google Scholar
• Caojin Z, Yigao H, Tao H, et al. Effects of low doses of aerosolized iloprost combined with tadalafil in treatment of adult congenital heart disease with severe pulmonary arterial hypertension. Chin Med J (Engl). 2014;127(5):975–977.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37(6):507–512.
   PubMed Web of Science ®Google Scholar
• Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardiol. 2008;125(3):416–417.
   PubMed Web of Science ®Google Scholar
• Singh TS, Kumar D, Basu S, Panja M, Mitra B. Tadalafil in the management of severe pulmonary artery hypertension. Indian Heart J. 2006;58(1):52–53.
   PubMedGoogle Scholar
• de Carvalho AC, Hovnanian AL, Fernandes CJ, Lapa M, Jardim C, Souza R. Tadalafil as treatment for idiopathic pulmonary arterial hypertension. Arq Bras Cardiol. 2006;87(5):e195–e197.
   PubMedGoogle Scholar
• Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2006;108(3):429–431.
   PubMed Web of Science ®Google Scholar
• Palmieri EA, Affuso F, Fazio S, Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med. 2004;141(9):743–744.
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin. 2009;25(10):2479–2485.
   PubMed Web of Science ®Google Scholar
• Berman-Rosenzweig E, Arneson C, Klinger JR. Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. Pulm Circ. 2014;4(1):45–52.
   PubMed Web of Science ®Google Scholar
• Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Gender differences in response to tadalafil in pulmonary arterial hypertension. Chest. 2015;147(1):188–197.
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009; 98(12):4962–4974.
   PubMed Web of Science ®Google Scholar
• Kohno H, Ichida F, Hirono K, et al. Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. Ther Drug Monit. 2014;36(5):576–583.
   PubMed Web of Science ®Google Scholar
• Bendayan D, Shitrit D, Kramer MR. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology. 2008;13(6):916–918.
   PubMed Web of Science ®Google Scholar
• Affuso F, Cirillo P, Ruvolo A, Carlomagno G, Fazio S. Long term combination treatment for severe idiopathic pulmonary arterial hypertension. World J Cardiol. 2010;2(3):68–70.
   PubMedGoogle Scholar
• Faruqi S, Fathi H, Morice AH. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. Int J Cardiol. 2010;144(3):e43–e45.
   PubMed Web of Science ®Google Scholar
• Maki H, Yao A, Inaba T. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. Int Heart J. 2011;52(5):323–326.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Oudiz RJ, Beardsworth A, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632–643.
   PubMed Web of Science ®Google Scholar